PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 43.25
Bid: 42.50
Ask: 44.00
Change: -0.25 (-0.57%)
Spread: 1.50 (3.529%)
Open: 43.50
High: 43.50
Low: 42.50
Prev. Close: 43.50
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: First Tin updates Tellerhauser estimates

Mon, 22nd Apr 2024 17:51

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

Zenith Energy Ltd - Aberdeen-based oil and gas company with assets in Africa and Italy - Launches a second bond exchange offer following the conclusion of its first offer in early April. The exchange is directed to the remaining noteholders of the euro 10.125% notes, US dollar 10.300% notes, and sterling 10.375% notes, all due January 27, 2024. The offer is to exchange the euro notes to 14.625% notes, the dollar notes to 14.800% notes, and the sterling to 14.875% notes, all due May 21, 2026. Zenith says the new bond exchange offer is due to "a significant number" of noteholders being unable to participate in the first bond offer due to difficulties faced by their chosen investment platform.

----------

Avacta Group PLC - Wetherby, England-based life sciences company - Issues 7.5 million new shares in settlement of the quarterly principal amount of GBP2.6 million and interest repayment of GBP620,000 in respect of the company's unsecured convertible bonds. Avacta says it will review how to settle its future quarterly bond repayments. Following this settlement, the principal remaining under the convertible bonds will be reduced to GBP35.70 million from GBP38.3 million.

----------

Ormonde Mining PLC - Dublin-based natural resources company with assets in Newfoundland and Scotland - Says its 36%-owned investee TRU Precious Metals Corp intends to carry out an exploration project this spring and summer at its Golden Rose project in Newfoundland. Exploration will focus on assessing the critical minerals potential associated with the deposit-bearing Cape Ray-Valentine Lake Shear Zone. Executive Chair Brian Timmons says: "Not only does Golden Rose have high-grade gold discoveries along the same structures as nearby deposits, but it is also highly prospective for copper and other critical minerals. With a number of large gold companies seeking to diversify their exposure through copper, we believe this multi-mineral resource focus will make Golden Rose even more attractive for M&A in the future."

----------

First Tin PLC - tin development company with projects in Germany and Australia - Updates the mineral resource estimate for its 100%-owned Tellerhauser tin project in Germany, after analysis from an independent geological consultant. The total indicated and inferred tin mineral resource estimate has increased by 35% from the 2019 estimate to 138,600 tonnes from 102,900 tonnes. Estimates of total indicated only tin has increased 37% to 45,000 tonnes from 32,700. Chief Executive Officer Bill Scotting says: "This increased MRE is a large step forward for us at our Tellerhauser project in Germany. In a world requiring more tin, but with few advanced projects such as ours, increasing our resources from historic drilling data mining is extremely valuable. The additional data from the equivalent of 1311 drillholes and channel samples has enabled a more robust resource model with significantly more tonnes."

----------

By Hugh Cameron, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
1 Jun 2021 20:24

TRADING UPDATES: CML plans AIM move; IronRidge to demerge gold assets

TRADING UPDATES: CML plans AIM move; IronRidge to demerge gold assets

Read more
1 Jun 2021 11:16

Avacta confident despite filing delay for Covid-19 antigen test

(Sharecast News) - Diagnostics and cancer therapies developer Avacta Group updated the market on its CE-mark submission for its 'AffiDX' SARS-CoV-2 antigen lateral flow test for professional use.

Read more
28 May 2021 11:29

Avacta still waiting on response from UK regulator over Covid test

Avacta still waiting on response from UK regulator over Covid test

Read more
28 May 2021 07:29

Avacta still waiting on MHRA approval for Covid-19 test

(Sharecast News) - Cancer therapies and diagnostics developer Avacta Group responded to speculation around the CE-mark submission for its SARS-CoV-2 antigen lateral flow test on Friday.

Read more
10 May 2021 11:13

IN BRIEF: Avacta to sell Covid-19 test in UK in "coming days"

IN BRIEF: Avacta to sell Covid-19 test in UK in "coming days"

Read more
22 Apr 2021 12:17

Avacta sees Covid-19 tests driving earnings after reporting 2020 loss

Avacta sees Covid-19 tests driving earnings after reporting 2020 loss

Read more
20 Apr 2021 15:18

Avacta reports positive data for Covid-19 test product

(Sharecast News) - Diagnostics and cancer therapies developer Avacta announced positive data from the clinical validation of its 'AffiDX' SARS-CoV-2 antigen lateral flow test on Tuesday.

Read more
20 Apr 2021 12:17

IN BRIEF: Avacta's rapid Covid-19 test is 98% sensitive in trial

IN BRIEF: Avacta's rapid Covid-19 test is 98% sensitive in trial

Read more
20 Apr 2021 11:35

AIM WINNERS & LOSERS: Warpaint tops outlook; Avacta's Covid test works

AIM WINNERS & LOSERS: Warpaint tops outlook; Avacta's Covid test works

Read more
15 Apr 2021 14:56

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
6 Apr 2021 13:53

IN BRIEF: Avacta in global Affimer distribution agreement with Abcam

IN BRIEF: Avacta in global Affimer distribution agreement with Abcam

Read more
6 Apr 2021 11:03

Avacta signs global distribution deal with Abcam

(Sharecast News) - Cancer therapies and diagnostics developer Avacta Group has entered into a global distribution agreement with Abcam, it announced on Tuesday, to sell its recently-developed SARS-CoV-2 research 'ELISA Affimer' reagents.

Read more
25 Mar 2021 15:57

EXECUTIVE CHANGES: Ten Entertainment, Emmerson chairs step down

EXECUTIVE CHANGES: Ten Entertainment, Emmerson chairs step down

Read more
9 Mar 2021 20:19

IN BRIEF: Avacta Group signs diagnostic licensing deal with Biokit

IN BRIEF: Avacta Group signs diagnostic licensing deal with Biokit

Read more
9 Mar 2021 11:08

Avacta enters licence deal with Werfen subsidiary Biokit

(Sharecast News) - Cancer therapy and diagnostics developer Avacta has entered into a licence agreement with Werfen subsidiary Biokit, it announced on Tuesday, to incorporate 'Affimer' reagents into a Biokit in-vitro diagnostic product.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.